CytomX Therapeutics Stock Rises 8% After Astellas Pharma Milestone Payment & TCB Collaboration Agreement
January 31, 2023
Trending News ☀️
CYTOMX ($NASDAQ:CTMX): CytomX Therapeutics is a biopharmaceutical company that focuses on the development of Probody therapeutics to treat cancer and other diseases. The company’s stock rose 8% on Thursday after it was announced that it had received a $5M milestone payment from Astellas Pharma. The payment was the result of their Probody T-Cell Engaging Bispecific collaboration agreement, which has now produced its first clinical candidate. The partnership between CytomX and Astellas is focused on the development of conditionally activated TCB programs to target difficult-to-treat cancers. CytomX is eligible to receive preclinical, clinical and commercial milestones if their partnership with Astellas is successful.
The company is also working with various other pharmaceutical companies to develop Probody therapeutics for the treatment of diseases, including colorectal cancer, breast cancer and glioblastoma. The milestone payment and collaboration agreement have further strengthened the partnership between Astellas and CytomX and increased investors’ confidence in the company’s future prospects. With the potential for additional milestone payments, CytomX is well-positioned to continue its progress in developing new treatments for cancer and other diseases.
Share Price
CytomX Therapeutics stock rose 8% on Thursday after the company announced a milestone payment from Astellas Pharma and a collaboration agreement with TCB. The stock opened at $2.7 and closed at $2.8, representing a 6.1% increase from the previous day’s closing price of $2.6. This news comes as a welcome change for the company, which has largely been receiving negative media exposure in recent months. The news has been seen as a positive development for investors, who were likely expecting further negative news in the near future.
The 8% rise in the stock price is a sign that the market is starting to recognize CytomX Therapeutics’ potential and is willing to take a chance on the company’s future prospects. It remains to be seen whether or not the momentum will continue for CytomX Therapeutics, but the news of the collaboration agreement and milestone payment are certainly positive signs for investors. With any luck, this could be the start of a positive trend for the company, one that could see its stock price continue to rise in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cytomx Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 71.94 | -97.59 | -135.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cytomx Therapeutics. More…
| Operations | Investing | Financing |
| -140.59 | -1.8 | 1.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cytomx Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 226.49 | 198.02 | 0.43 |
Key Ratios Snapshot
Some of the financial key ratios for Cytomx Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.8% | – | -137.5% |
| FCF Margin | ROE | ROA |
| -197.9% | -160.3% | -27.3% |
VI Analysis
This score reflects its cashflow and debt, suggesting that it is able to ride out any crisis with relative safety. The company is classified as a ‘rhino’, which indicates that it has achieved moderate revenue or earnings growth. As such, investors who are looking for steady growth rather than rapid growth may find this company appealing. The company is strong in growth, but weak in dividend, profitability, and asset. Investors who are looking for growth and are not worried about dividends may be interested in this company. However, those investors who are looking for a more secure investment should look elsewhere as the company’s fundamentals may not be strong enough to guarantee a return on their investment. Overall, CYTOMX THERAPEUTICS is a company with potential, but investors should consider its weaknesses before investing in it. It may be worth considering other companies with better fundamentals if a more secure investment is desired. More…
VI Peers
CytomX’s lead product candidate, CX-072, is a CD37-targeting ADC in Phase 1 clinical development for the treatment of hematologic malignancies, solid tumors, and other diseases. The company is also developing CX-2009, an anti-CTLA-4 ADC, in Phase 1 clinical development for the treatment of solid tumors, and CX-2029, an anti-PD-L1 ADC, in Phase 1 clinical development for the treatment of solid tumors. CytomX’s main competitors are IO Biotech Inc, DICE Therapeutics Inc, and Aura Biosciences Inc. IO Biotech is a clinical-stage biopharmaceutical company that develops cancer immunotherapies. DICE Therapeutics is a biopharmaceutical company that develops cancer immunotherapies. Aura Biosciences is a clinical-stage biopharmaceutical company that develops cancer therapeutics.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of 2022, Incyte had a market capitalization of $67.43 million and a return on equity of -20.77%. The company’s products include Jakafi, a treatment for myelofibrosis and polycythemia vera; Iclusig, a treatment for chronic myeloid leukemia; and Jakafi, a treatment for acute graft-versus-host disease.
– DICE Therapeutics Inc ($NASDAQ:DICE)
DICE Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer. The company’s lead candidate is DICE-301, a small molecule inhibitor of the transcription factor E2F that is currently being evaluated in a Phase I/II clinical trial in patients with advanced solid tumors. DICE-301 has shown preliminary efficacy in patients with advanced solid tumors, including non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company is also developing DICE-201, a small molecule inhibitor of the transcription factor c-Myc, which is currently in preclinical development.
– Aura Biosciences Inc ($NASDAQ:AURA)
Aura Biosciences Inc is a clinical-stage biopharmaceutical company developing a new class of drugs called tumor-targeted photodynamic therapies (PDTs) for the treatment of solid tumors. PDTs are a type of cancer treatment that uses light to kill cancer cells. The company’s lead product candidate, AU-011, is a PDT that is being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. Aura Biosciences Inc has a market cap of $365.63M as of 2022 and a Return on Equity of -21.81%. The company’s products are still in development and have not yet been approved by the FDA.
Summary
CYTOMX Therapeutics has seen an 8% increase in its stock price following news of a milestone payment from Astellas Pharma and a collaboration agreement with TCB. Despite negative media exposure, the announcement has had a positive impact on the stock and investors are encouraged to take note of the company’s potential. CYTOMX Therapeutics is a biopharmaceutical company that develops novel cancer immunotherapies and targets cancer cells with proteolysis-targeting chimeric molecules. The company is focused on developing therapies for solid tumors, hematologic malignancies, and other diseases.
CYTOMX Therapeutics has multiple programs in preclinical and clinical development and is currently exploring additional collaborations and partnerships. Investors may find value in the company’s promising pipeline and exciting potential for growth in the near future.
